Developmental Cancer Therapeutics

发展性癌症治疗计划 摘要 发展性癌症治疗(DCT)计划自2012年以来有了很大的发展， 更加关注实体肿瘤肿瘤学和推动基础科学向 快速开展早期临床试验。在大卫·霍恩博士和爱德华·纽曼博士的领导下， DCT的中心主题和总体目标是内部开发新颖的、分子靶向的 难治性癌症的治疗和药物输送系统。尽管DCT延续了该计划的长期- 在评估通过行业合作开发的癌症治疗方面的长期实力，重点是 DCT计划是为了推进在希望之城癌症综合研究所取得的重要基础发现 中心(COHCCC)。为此，DCT确立了明确的科学目标，这些目标分为三个中心主题： 1)通过识别和验证新的分子癌症，支持靶向药物开发 靶点/途径和开发相应的药理药物；2)开发新的药物释放 提高临床结果的特异性和有效性的平台；以及3)将基本发现和临床前 对早期临床试验的研究。DCT计划跨越八个部门，包括 共有29名成员，其中12名是基础研究人员，17名是临床医生/临床科学家。通过 计划，在基础科学家和临床科学家之间促进了密切的计划内和计划间合作 研究人员，这反过来又导致目前处于临床状态的COH启动药物的数量增加 调查。在前一批款期间，已经建立了重要的基础设施，以创建 强大的转化性研究计划，更加关注实体肿瘤肿瘤学，导致持续的 新治疗方法的流动为早期临床试验做好准备。重点放在速度和精度上 医药。只有GLP毒性研究和一些配方工作外包给外部，DCT计划可以 快速将发现转化为临床研究。该计划通过战略招聘进一步得到加强 关键教员(Chen、Fakih、Fong、Gold和Salgia)、实施药物发现管道和cGMP 通过COH的内部化学cGMP制造小分子药物的能力，如COH29 综合设施。在下一个资助期内，我们期待着我们的新疗法的强劲翻译 从发现阶段到首个人类临床试验的方法，并继续与其他 区域和国家综合性癌症中心。 成员：29名计划成员，代表8个基础和临床科室 出版物总数：503篇。20.1%的方案内；36.4%的方案间；41.2%的机构间 资金：4,751,305美元，经同行审查；其中1,794,235美元为NCI资金

Developmental Cancer Therapeutics Program ABSTRACT The Developmental Cancer Therapeutics (DCT) Program has evolved considerably since 2012 with an increased focus on both solid tumor oncology and the translational aspects of advancing basic science into early-phase clinical trials in rapid fashion. Under the leadership of David Horne, PhD and Edward Newman, PhD, the central theme and overarching goal of DCT are the in-house development of novel, molecularly targeted therapies and drug delivery systems for intractable cancers. Although DCT has continued the Program's long- standing strength in evaluating cancer therapeutics developed through industry partnerships, the emphasis of the DCT Program is to advance important basic discoveries made at the City of Hope Cancer Comprehensive Center (COHCCC). To this end, DCT has established clear scientific goals that fall under three central themes: 1) Support target-directed drug development by identifying and validating new molecular cancer targets/pathways and developing corresponding pharmacological agents; 2) Develop novel drug delivery platforms to improve specificity and efficacy of clinical outcomes; and 3) Translate basic discovery and preclinical studies into early-phase clinical trials. The DCT program extends across eight departments and encompasses a total of 29 Members, of which 12 are basic researchers and 17 are clinicians/clinician scientists. Through the Program, close intra- and inter-programmatic collaborations are fostered among basic scientists and clinical investigators, which in turn has yielded an increase in the number of COH-initiated agents currently under clinical investigation. During the previous grant period, significant infrastructure has been established for the creation of a strong translational research program with greater focus on solid tumor oncology, resulting in a continuous flow of new therapeutic approaches poised for early-phase clinical trials. The emphasis is on speed and precision medicine. With only GLP toxicity studies and some formulation work contracted outside, the DCT Program can rapidly translate discoveries to the clinic. This Program has been further enhanced by the strategic recruitment of key faculty (Chen, Fakih, Fong, Gold, and Salgia), implementation of a drug discovery pipeline, and cGMP manufacturing capability for small molecule drugs, such as COH29, through COH’s in-house Chemical cGMP Synthesis Facility. During the next funding period, we anticipate robust translation of our new therapeutic approaches from the discovery phase to first-in-human clinical trials and continued close collaboration with other regional and national Comprehensive Cancer Centers. Membership: 29 Program Members representing 8 basic and clinical departments Publications: 503 total. 20.1% intra-programmatic; 36.4% inter-programmatic; 41.2% inter-institutional Funding: $4,751,305 peer-reviewed; $1,794,235 of which is NCI funding